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Quality of Life (AQoL-4D) produces robust utility values in adults with
psychotic illness, and identify health inequalities compared with the
general population. Methods: The AQoL-4D was completed by 1613
individuals with an International Classiﬁcation of Diseases, Tenth Revision,
psychotic illness in the 2010 Australian National Survey of Psychosis.
Utilities were assessed for this sample and 20 subgroups, and were
compared with general population norms. Modiﬁed Cohen d was used
as an index of effect size. Utilities were collapsed into 10 health-
related quality-of-life (HRQOL) bands or decades. Results: HRQOL in
people with psychotic illness was half of the maximum achievable
utility (half-“full health”) with a mean utility of 0.49 (95% conﬁdence
interval [CI] 0.48–0.51), and showing substantial variability across
subgroups. Participants with essentially normal functioning had the
highest mean utility (0.72; 95% CI 0.68–0.77), and those with very poor
perceived mental health had the lowest (0.22; 95% CI 0.18–0.26). These
subgroups showed the most variability. Negative symptoms also gaveee front matter Copyright & 2018, International S
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.Neil@utas.edu.au.rise to substantial variation. Among diagnostic categories, only
depressive psychosis had a large effect relative to delusional disor-
ders. The distribution of utilities in people with psychotic
illness differed markedly from that in the general population, with
6.8% versus 47.2% having values in the highest decade (>0.90–1.00).
Utilities were lower in every age group in people with psychosis.
Conclusions: Profound HRQOL impacts are revealed by the AQoL-4D
in people with psychotic illness, and marked variations in utilities
were observed for key subjective and objective measures. We provide
a suite of utility values for economic modeling studies and recom-
mend the AQoL-4D for assessing HRQOL in people with psychotic
illness.
Keywords: economic modeling, health inequalities, psychotic
disorders, schizophrenia, utility assessment.
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Psychotic illness comprises a heterogeneous group of disorders in
which an individual’s understanding and experience of reality is
distorted, reﬂected in disturbances in the formation and content
of their thoughts. The impact of psychotic illness is profound
with mental, physical, and social well-being affected. Currently,
there is no accepted source of valid and reliable utilities to
assess health-related quality-of-life (HRQOL) impacts. Commonly
used multi-attribute utility instruments (MAUIs), including theEuroQol ﬁve-dimensional questionnaire (EQ-5D), the six-
dimensional health state short form (SF-6D), and the 15D, are
considered problematic [1–4]. Concerns raised include insensitiv-
ity (inability to detect lower HRQOL in people with psychosis) and
the lack of responsiveness to disease-speciﬁc symptoms and
other phenomena. This lack of unbiased instruments compro-
mises decision making. One instrument that has not been
considered in the debate of the appropriateness and usefulness
of MAUIs for psychotic disorders is the four-dimensional Assess-
ment of Quality of Life (AQoL-4D) instrument [5].ociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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6D) in several important aspects. First, the AQoL instruments are
the only MAUIs constructed using psychometric principles [6],
including having a minimum of three items measuring the same
underlying latent construct. Second, there are major differences
with respect to their descriptive systems (see Appendix 1 in
Supplemental Materials found at https://doi.org/10.1016/j.jval.
2018.02.012); the AQoL gives greater weight to social disability
than do other instruments [7], and differences in descriptive/
classiﬁcation systems are the principal determinants of non-
equivalence between MAUIs and the utilities they assess [8].
Finally, the AQoL-4D has good lower end sensitivity and has been
validated for use in people with psychotic illness [9]. Together,
these factors indicate that the AQoL-4D should have major
advantages in the assessment of utilities in people with psycho-
sis. We aimed to establish whether the AQoL-4D produces robust
utility values in adults with psychotic illness, and to identify
health inequalities compared with the general population.Methods
Data for people with psychotic illness were collected as part of
the 2010 Australian National Survey of Psychosis—the Survey of
High Impact Psychosis [10–12], a large population-based cross-
sectional survey of people with psychosis aged 18 to 64 years. The
survey was undertaken at seven sites in ﬁve Australian states,
and covered an estimated resident population of 1,464,923
people—about 10% of the Australian population in the age range.
A two-phase design was used.
In phase 1 (March 2010), screening for individuals likely to
meet diagnostic criteria for psychosis occurred in public speci-
alized mental health services (inpatient, outpatient, ambulatory,
and community mental health services) and nongovernmental
organizations supporting people with mental illness. Adminis-
trative records were searched to identify individuals with psy-
chosis who were in contact with public mental health services in
the 11 months before census but not in the census month. In
phase 2 (April to December 2010), 1825 of the 7955 people who
were screened positive for psychosis in phase 1 were randomly
selected for interview, stratiﬁed by age group (18–34 years and
35–64 years). At the interview, 1642 of this sample met Interna-
tional Classiﬁcation of Diseases, Tenth Revision (ICD-10) criteria for a
psychotic disorder.
Interview data were collected on symptomatology, substance
use, disability, cognitive functioning, physical health, mental and
physical health service utilization, medication use, education,
employment, housing, community sector support, and HRQOL.
For full methodological details, refer to the studies by Morgan
et al. [10–12].
The study was approved by institutional human research
ethics committees at all seven study sites. Participants gave
written informed consent after receiving full information on the
study.
Basic Analytic Approach
HRQOL was assessed for individuals meeting ICD-10 criteria for a
psychotic disorder across a range of 20 subjective and objective
general and illness-related characteristics, and comparisons were
made with relevant population norms.
Measures
The AQoL-4D
HRQOL was assessed using the AQoL-4D [5,7]. The AQoL-4D is the
original of a suite of AQoL instruments (4D, 6D, 7D, and 8D) and
was developed with speciﬁc reference to the World HealthOrganization’s 1948 deﬁnition of health: “a state of complete
physical, mental and social well-being and not merely the
absence of disease or inﬁrmity” [5]. It comprises ﬁve health
dimensions, each with three items of four levels of severity (see
Appendix 1 in Supplemental Materials). Four dimensions are
used in the assessment of utility: independent living, social
relationships, psychological well-being, and physical senses.
With the AQoL-4D, utilities can range from −0.04, for states
worse than death, to 1.00, full health (see Appendix 2 in
Supplemental Materials found at https://doi.org/10.1016/j.jval.
2018.02.012). Utilities were calculated using the standard algorithm
provided as AQoL-4D Algorithm for SPSS (http://www.aqol.com.
au/scoring-algorithms/82.html). Utilities were also collapsed into
decades, 10 equally spaced bands of utility scores, except for the
lowest, which was extended to accommodate states worse than
death. The bands thus ranged from (−0.04 to 0.10) to (>0.90 to 1.00).
The population utilities used for comparison [13] were based
on data collected in the course of the 2007 Australian National
Survey of Mental Health and Wellbeing, a nationally representa-
tive, face-to-face household survey of 8841 community residents
aged 16 to 85 years, undertaken by the Australian Bureau of
Statistics [14].
Demographic and functioning measures
Demographic variables comprised primary homelessness (sleep-
ing rough) in the past 12 months (yes, no), difﬁculty reading and/
or writing (self-report: yes, no), and completed ﬁnal year of
schooling (yes, no). Functioning was assessed by the inter-
viewers, who were mental health professionals trained in the
use of the survey instruments. Premorbid IQ was measured using
the National Adult Reading Test [15] summary scores, and
categorized as above, below, or within 1 SD of the sample mean
(98.0 ± 11.3). Current cognitive function was based on the Digit-
Symbol Coding task summary scores from the Repeatable Battery
for Assessment of Neuropsychological Status [16], and catego-
rized as above, below, or within 1 standard deviation (SD) of the
sample mean (38.3 ± 10.6). Global independent functioning was
measured using the Multidimensional Scale of Independent
Functioning [17] and categorized as essentially normal, very mild
disability, somewhat disabled, moderately disabled, signiﬁcantly
disabled, extremely disabled, and totally disabled. Social func-
tioning was rated as no dysfunction, obvious dysfunction, or
severe dysfunction.
General health variables
General health variables, for which there are published Austral-
ian norms [13], included perceived mental health status and
perceived physical health status (excellent, good, fair, poor, very
poor), self-reported lifetime cardiovascular disease (CVD; yes, no),
and self-reported current and lifetime depressive symptoms
(yes, no).
Disorder-speciﬁc health variables
Disorder-speciﬁc health variables included ICD-10 diagnosis
(schizophrenia, schizoaffective disorder, bipolar disorder with
psychotic features, depressive psychosis, and delusional disor-
ders), course of illness (single episode, multiple episodes with
good recovery, multiple episodes with partial recovery, continu-
ous chronic, and continuous chronic with deterioration), duration
of illness (o1 year, 1 year, 2–4 years, 5–9 years, 10–19 years, 20–29
years, and ≥30 years), current and lifetime suicidal ideation
(attempted suicide or ideation present at least 1 week, present
at least 2 weeks, and present at least 1 month), number of
negative symptoms, and presence of current positive symptoms
and/or symptoms of mania and/or depressive symptoms.
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signs or symptoms, on the basis of those identiﬁed by Carpenter
et al. [18] (restricted effect, diminished emotional range, poverty
of speech, curbing of interest, diminished sense of purpose, and
diminished social drive) and operationalized through the Sched-
ules for Clinical Assessment in Neuropsychiatry [19]. Attribution
(whether the symptoms were primary or secondary to the
psychotic illness) was not taken into account. Scores ranged from
0 to 6. Positive symptoms comprised the presence of subjective
thought disorder and/or delusions and/or hallucinations.1.4 1.3 2.2 2.9 2.4
4.1
0
5
AQoL Decades
Fig. 1 – Distribution of utility scores for the Australian
population with psychotic illness (Second Australian
National Survey of Psychosis—Survey of High Impact
Psychosis) and the general population by AQoL utility
decade. Note. General Australian population data were
collected during the 2007 National Health and Mental
Wellbeing Survey [13]. Teal squares: psychosis; orange
triangles: general population. AQoL, Assessment of Quality
of Life.
1.00Statistical Analysis
Data were weighted to achieve representativeness of the
screened positive sample, with sampling weights reﬂecting site
and age strata of the interviewed sample. Simple descriptive
statistics comprising mean and 95% conﬁdence interval (CI),
median, and interquartile range (IQR) were assessed using SPSS
version 22 (SPSS Inc., Chicago, IL), the Complex Samples Descrip-
tives procedure. The median and IQR were ascertained with
reference to the cumulative frequency distribution.
The observed distribution of AQoL utilities was approximately
symmetric (skewness −0.09), but platykurtic (kurtosis −1.13).
Utility data were assessed untransformed.
Analyses of differences between groups within the sample
were based on analysis of variance using the Pearson χ2 test [20]
and a comparison of group CIs, both assessed using the SPSS
Complex Samples General Linear Model procedure. Additional
comparisons were considered statistically signiﬁcant when 95%
CIs did not overlap, a conservative approach because some
overlapping CIs may be signiﬁcant [21].
Effect size (ES) has been used as the measure of magnitude of
effect because it is unknown whether the clinical minimally
important difference speciﬁed for the AQoL-4D is applicable in
population samples and across the adult life span [13]. This
difference, assessed at 0.06, was based primarily on trials with
older adults [22]. A modiﬁed form of Cohen dwas calculated as an
index of ES [23]; this used the SD of the reference category rather
than an estimate pooling that of all groups [24]. The reference
category was the ﬁrst category, unless otherwise speciﬁed. ESs
were classiﬁed as small (0.20), medium (0.50), and large (0.80) [23].
Comparisons against AQoL population norms used the Welsh
approximate t test [25].0.58
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Fig. 2 – Mean AQoL utility scores with 95% CIs for the
Australians with psychotic illness (Second Australian
National Survey of Psychosis—Survey of High Impact
Psychosis) and the general Australian population by age
group. Note. General Australian population data were
collected during the 2007 National Health and Mental
Wellbeing Survey [13]. Teal squares: psychosis; orange
triangles: general population. AQoL, Assessment of Quality
of Life; CI, conﬁdence interval.Results
Of the 1642 participants who met ICD-10 criteria for a psychotic
disorder at interview, 1613 (98.2%) provided sufﬁcient data for
AQoL utility assessment. Utilities ranged from −0.04 (n ¼ 5 [0.3%])
to 1.00 (n ¼ 41 [2.6%]). The mean AQoL utility was 0.49 (95% CI
0.48–0.51) with a median of 0.52 (IQR 0.26–0.73), signiﬁcantly lower
than the general population utility of 0.81 (t ¼ 42.75; df ¼ 2129).
The distribution of utilities by decade differed markedly from
that of the general population (Fig. 1). Most strikingly, utilities for
people with psychotic illness were almost uniformly distributed,
whereas they were highly skewed toward the healthier decades
for the general population. Almost half of the general population
(47.2%) had a utility in the highest decade (>0.90 to 1.00), whereas
for participants with psychosis, the highest decade had the
lowest proportion of any decade at 6.8%.
Mean utilities were lower in people with a psychotic disorder
in all age groups, and there was a greater decline in utility with
increasing age for the psychosis sample than for the general
population (Fig. 2). This divergence with age increased in the
fourth and ﬁfth decades of life.With the exception of premorbid IQ, variations in demo-
graphic, cognitive, and functional variables were correlated with
variations in estimated utility and demonstrated meaningful
differences in utility, that is, greater than the minimally impor-
tant difference of 0.06 (Table 1). The largest difference in utility
between categories for these variables was 0.43 for global inde-
pendent functioning, with utilities ranging from 0.72 (95% CI 0.68–
0.77) for essentially normal functioning on the Multidimensional
Scale of Independent Functioning to 0.29 (95% CI 0.23–0.35) for
extremely disabled (ES −0.58 to −2.09). A large effect was also
assessed for social functioning (ES −0.68 to −1.20) for which the
maximum difference in utility between categories was 0.30.
All general health variables were correlated with variation in
estimated utility (Table 1), with the variations all statisically and
Table 1 – AQoL utility scores by demographic, cognitive, functional, and general health variables.
Variable n Mean SD 95% CI Median IQR ES* P value
Primary homelessness in last 12 mo† 0.002
No 1528 0.50 0.28 0.49–0.52 0.52 0.25–0.74
Yes 85 0.40 0.34–0.46 0.36 0.15–0.59 −0.35
Year 12 completion‡ 0.001
Yes 517 0.54 0.28 0.51–0.57 0.57 0.29–0.77
No 1077 0.47 0.46–0.49 0.48 0.22–0.71 −0.25
Difﬁculty in reading and/or writing§ o0.001
No 1317 0.52 0.28 0.50–0.53 0.54 0.28–0.75
Yes 293 0.39 0.36–0.43 0.33 0.13–0.64 −0.47
Premorbid IQ|| 0.338
Above average 251 0.51 0.27 0.48–0.55 0.53 0.27–0.73
Average 891 0.52 0.50–0.54 0.55 0.29–0.76 0.04
Below average 236 0.49 0.45–0.53 0.51 0.23–0.73 −0.07
Current cognitive function¶ o0.001
Above average 216 0.58 0.28 0.55–0.62 0.62 0.38–0.80
Average 1018 0.52 0.50–0.54 0.54 0.28–0.74 −0.22
Below average 207 0.41 0.55–0.62 0.37 0.12–0.64 −0.61
Social functioning# 0.25 o0.001
No dysfunction 584 0.63 0.61–0.66 0.67 0.49–0.84
Obvious dysfunction 700 0.46 0.44–0.48 0.47 0.26–0.67 −0.68
Severe dysfunction 328 0.33 0.30–0.36 0.23 0.11–0.52 −1.20
Global independent functioning** o0.001
Essentially normal functioning 87 0.72 0.21 0.68–0.77 0.73 0.58–0.89
Very mild disability 301 0.60 0.56–0.63 0.64 0.39–0.80 −0.58
Somewhat disabled 413 0.52 0.50–0.55 0.55 0.31–0.74 −0.97
Moderately disabled 446 0.45 0.42–0.48 0.46 0.19–0.69 −1.32
Signiﬁcantly disabled 269 0.41 0.38–0.45 0.38 0.18–0.63 −1.51
Extremely disabled 79 0.29 0.23–0.35 0.22 0.10–0.49 −2.09
Totally disabled 18 0.30 0.16–0.44 0.15 0.01–0.60 −2.05
Perceived mental health†† o0.001
Excellent 167 0.67 0.28 0.62–0.72 0.75 0.47–0.91
Very good 348 0.63 0.60–0.65 0.68 0.46–0.82 −0.14
Good 531 0.49 0.46–0.51 0.51 0.25–0.71 −0.65
Fair 395 0.40 0.38–0.43 0.41 0.18–0.61 −0.98
Poor 118 0.22 0.18–0.26 0.17 0.06–0.33 −1.63
Perceived physical health‡‡ o0.001
Excellent 96 0.64 0.28 0.58–0.70 0.70 0.36–0.89
Very good 276 0.61 0.58–0.64 0.66 0.40–0.82 −0.11
Good 560 0.55 0.52–0.57 0.58 0.33–0.75 −0.32
Fair 463 0.43 0.40–0.46 0.43 0.19–0.65 −0.74
Poor 214 0.30 0.26–0.34 0.25 0.06–0.47 −1.20
Cardiovascular disease§§ o0.001
No 1419 0.52 0.28 0.50–0.53 0.54 0.28–0.75
Yes 189 0.34 0.30–0.39 0.27 0.10–0.55 −0.65
Depressive symptoms: lifetime|||| o0.001
No 331 0.57 0.29 0.53–0.60 0.62 0.31–0.82
Yes 1282 0.48 0.46–0.49 0.49 0.24–0.71 −0.31
Depressive symptoms: current¶¶ o0.001
No 1153 0.56 0.28 0.54–0.57 0.59 0.32–0.78
Yes 460 0.34 0.32–0.36 0.32 0.12–0.53 −0.80
CVD and depressive symptoms## o0.001
Neither present 1025 0.57 0.27 0.56–0.59 0.61 0.36–0.80
CVD only 124 0.41 0.35–0.46 0.33 0.15–0.67 −0.59
Depressive symptoms only 394 0.36 0.34–0.39 0.34 0.15–0.55 −0.78
CVD and depressive symptoms present 65 0.23 0.18–0.29 0.17 0.06–0.35 −1.26
SD pertains to the reference category.
ANOVA, analysis of variance; AQoL, Assessment of Quality of Life; CI, conﬁdence interval; CVD, cardiovascular disease; ES, effect size; IQ,
intelligence quotient; IQR, interquartile range; SD, standard deviation.
* Modiﬁed Cohen d, with reference category as the ﬁrst category.
† Primary homeless—sleeping rough in the past 12 mo. ANOVA, adjusted Wald F ¼ 9.934; df ¼ 1, 1611; P ¼ 0.002.
‡ ANOVA, adjusted Wald F ¼ 12.622; df ¼ 3, 1609; P ¼ 0.001 (included two missing categories).
§ ANOVA, adjusted Wald F ¼ 22.246; df ¼ 1, 1610; P o 0.001.
|| ANOVA, adjusted Wald F ¼ 1.086; df ¼ 2, 1375; P ¼ 0.338.
¶ ANOVA, adjusted Wald F ¼ 19.428; df ¼ 2, 1438; P o 0.001.
# ANOVA, adjusted Wald F ¼ 135.824; df ¼ 2, 1609; P o 0.001.
** ANOVA, adjusted Wald F ¼ 37.373; df ¼ 6, 1606; P o 0.001.
†† ANOVA, adjusted Wald F ¼ 94.214; df ¼ 4, 1554; P o 0.001.
‡‡ ANOVA, adjusted Wald F ¼ 54.173; df ¼ 4, 1604; P o 0.001.
§§ ANOVA, adjusted Wald F ¼ 57.039; df ¼ 1, 1606; P o 0.001.
|||| ANOVA, adjusted Wald F ¼ 23.406; df ¼ 1, 1611; P o 0.000.
¶¶ ANOVA, adjusted Wald F ¼ 207.477; df ¼ 1, 1611; P o 0.001.
## ANOVA, adjusted Wald F ¼ 93.837; df ¼ 3, 1604; P o 0.001.
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differences in perceived mental health (ES −0.14 to −1.63), the
presence of lifetime CVD and/or current depressive symptoms (ES
−0.59 to −1.26), and perceived physical health (ES −0.11 to −1.20).
The difference in mean utility across the categories for each
variable was 0.45, 0.34, and 0.34, respectively.
The concurrent consideration of current depressive symp-
toms and lifetime CVD suggested a cumulative effect. When
neither condition was present, the mean utility was 0.57, but 0.41
in the presence of lifetime CVD alone, 0.36 for current depressive
symptoms alone, and 0.23 when both conditions were present.
Meanwhile, the mean utilities for current depressive symptoms
and lifetime CVD when considered individually were comparable
at 0.34 (95% CI 0.32–0.36) and 0.34 (95% CI 0.30–0.39), respectively,
and no different from current depressive symptoms alone.
Nevertheless, the corresponding ESs were large (ES −0.80), mod-
erate (ES −0.65), and almost large (ES −0.78). Together these
results support the sensitivity of the AQoL-4D in people with
psychotic illness.
The sensitivity of the instrument was also reﬂected in the
difference in utility between the “equivalent” categories for life-
time and current depression. For the presence of symptoms, the
difference was 0.14, given mean utilities of 0.48 (95% CI 0.46–0.49)
and 0.34 (95% CI 0.32–0.36), respectively, but only 0.01 for no
symptoms, given mean utilities of 0.57 (95% CI 0.53–0.60) and 0.56
(95% CI 0.54–0.57), respectively.
All disease-speciﬁc variables were correlated with variation in
estimated utility (Table 2), and the variations in utility were all
statisically and meaningfully different at least between the
highest and the lowest categories. For the major diagnostic
groupings and relative to delusional disorders, only depressive
psychosis had a large effect (ES −0.82), and schizoaffective
disorders a small effect (ES −0.25). The mean utility for people
with depressive psychosis at 0.32 (95% CI 0.26–0.39) was signiﬁ-
cantly and meaningfully lower than for the population with
psychotic illness, whereas that for delusional disorders, at 0.55
(95% CI 0.49–0.61), was higher. Otherwise, there were clear effects
for course and duration of illness, negative symptoms,
co-occurrence of mania, positive and/or current depressive
symptoms, and suicidal ideation (lifetime and current) on esti-
mated utility.
The reduction in utility associated with increasing numbers of
negative symptoms plateaued at about four symptoms with
mean utilities of 0.40 (95% CI 0.36–0.43), 0.38 (95% CI 0.34–0.42),
and 0.39 (95% CI 0.35–0.44) for four, ﬁve, and six symptoms,
respectively. Cumulative effects were noted for the co-occurrence
of mania and positive and/or current depressive symptoms. A
negligible effect was assessed for mania alone (ES −0.15), an
almost moderate effect for positive symptoms alone (ES −0.46), a
moderate effect for mania and positive symptoms together
(ES −0.62), and large effects for all other symptom categories, all
of which included current depressive symptoms either alone or
in combination with mania and/or positive symptoms. Utilities
ranged from 0.62 (95% CI 0.60–0.64) for no symptoms to 0.29 (95%
CI 0.24–0.34) for the presence of all three symptom groups
(ES −1.27).
People with current (in the past 4 weeks) suicidal ideation had
the lowest mean utility (0.24; 95% CI 0.17–0.30) among the
disorder-related health measures. There was an approximately
0.20 difference in utility between the duration categories (actual
attempt or at least 1 week, at least 2 weeks, and at least 1 month)
for lifetime and current suicidal ideation except for the category
“not present,” for which the difference was not quite mean-
ingfully different at 0.04.
There was no meaningful difference in utilities between those
who had experienced lifetime suicidal ideation and those who
had experienced lifetime depression. There were, however,meaningful differences in utility for those experiencing current
depression and those experiencing current suicidal ideation of 2
weeks in the past month and for the past month, at 0.06 and 0.10,
respectively.Discussion
This study extends the assessments of the burden of psychotic
disorders arising from the 2010 Australian National Survey of
Psychosis [10,12,26], establishing the extent of HRQOL inequal-
ities faced by people living with psychotic illness. In addition, we
have established the robustness of AQoL-4D utilities in this
population and provided a unique suite of utilities across a range
of key objective and subjective general health and disease-
speciﬁc measures, values that can be used in future economic
modeling studies. The evidence also supports the use of these
breakdowns in analyses for individual disorders except depres-
sive psychosis and delusional disorders. We have also found that
the AQoL-4D’s clinical minimally important difference in utility
of 0.06 is supported at the population level, because only differ-
ences of this magnitude had at least a small and statistically
signiﬁcant ES.
Psychotic illness was conﬁrmed as having profound HRQOL
impacts underpinned by a markedly different distribution of
utilities to the general population. The mean utility of 0.49
equates to half the maximum utility of 1.00 (full health), and is
consistent with the mean utility of 0.50 from the original
validation study of the AQoL-4D in people with psychotic illness
[9]. The Herrman et al. [9] study was undertaken in community-
dwelling patients with a long-standing psychotic disorder who
were attending an inner-city mental health service (N ¼ 173).
The validity of the AQoL-4D is further highlighted when we
compare our results with those obtained for other chronic health
conditions. For example, the mean utility for persons with
psychotic illness was signiﬁcantly and meaningfully lower than
for persons enrolled in chronic disease management programs
(n ¼ 1999) [27], both overall (0.55, SD ¼ 0.32) and by age group
(data not shown). Within this program the highest reported
utility was for participants whose primary health condition was
diabetes (without peripheral vascular complications) (0.62, SD ¼
0.31; n ¼ 215), and it was the lowest in those with aged care and
complex needs (0.33, SD ¼ 0.25; n ¼ 180). We found AQoL-4D
utilities to be sensitive, associated with all but one objective and
subjective general and disease-speciﬁc variable. Furthermore,
there were differences in utility between variables (e.g., lifetime
and current depression), between groups (e.g., ICD-10 diagnoses),
and variation across categories within a given variable. Cumu-
lative effects were indicated for several variables including
comorbid CVD and current depressve symptoms, co-occurring
symptoms of mania, and positive and depressive symptoms.
“Dose-response effects” were also observed within deﬁned sub-
groups; ﬂoor effects, however, constrained some of these, such as
that found when the number of negative symptoms reached four.
These relationships have not been comprehensively demon-
strated with other MAUIs [2,4].
Saarni et al. [2] (n ¼ 267) found no signiﬁcant association
between utilities assessed using both 15D and EQ-5D and positive
symptoms (−0.05; −0.13), disorganization (0.04; 0.14), and manic
symptoms (0.05; 0.13) among individuals with a psychotic dis-
order. Nevertheless, signiﬁcant but small associations were found
for depressive symptoms (−0.17; −0.19), course of disorder (−0.25;
−0.24), and outcome (−0.24; −0.21). Negative symptoms were not
signiﬁcantly associated with utility using the 15D, but were for
the EQ-5D (−0.16; −0.25).
In the study by Roberts et al. [4] (n ¼ 81), a lower mean utility
was assessed for depressive conditions than for psychosis using
Table 2 – AQoL utility scores by disorder-related health measures.
Variable n Mean SD 95% CI Median IQR ES* P
value
Diagnosis: DIP ICD-10† o0.001
Schizophrenia 838 0.51 0.49–0.53 0.53 0.26–0.74 −0.14
Schizoaffective disorder 290 0.48 0.44–0.52 0.49 0.22–0.74 −0.25
Bipolar disorder with psychotic features 316 0.51 0.47–0.54 0.52 0.26–0.73 −0.14
Depressive psychosis 81 0.32 0.26–0.39 0.24 0.07–0.50 −0.82
Delusional disorders 88 0.55 0.28 0.49–0.61 0.53 0.32–0.77
Course of illness‡ o0.001
Single episode, good recovery 106 0.63 0.27 0.57–0.68 0.66 0.43–0.88
Multiple episodes, good recovery 489 0.60 0.58–0.63 0.65 0.42–0.80 −0.07
Multiple episodes, partial recovery 516 0.48 0.45–0.50 0.49 0.26–0.69 −0.52
Continuous chronic 337 0.42 0.39–0.45 0.41 0.19–0.64 −0.77
Continuous chronic with deterioration 165 0.32 0.28–0.37 0.22 0.11–0.56 −1.11
Duration of illness§ o0.001
o1 y 34 0.63 0.27 0.52–0.73 0.68 0.39–0.87
1 y 53 0.54 0.46–0.62 0.58 0.26–0.76 −0.34
2–4 y 173 0.55 0.50–0.59 0.58 0.29–0.78 −0.30
5–9 y 330 0.52 0.49–0.55 0.56 0.28–0.74 −0.41
10–19 y 581 0.51 0.49–0.54 0.53 0.27–0.75 −0.45
20–29 y 275 0.44 0.41–0.48 0.44 0.21–0.66 −0.71
≥30 y 167 0.41 0.36–0.46 0.39 0.13–0.67 −0.82
Negative symptoms|| o0.001
0 228 0.70 0.22 0.67–0.73 0.74 0.58–0.86
1 241 0.58 0.55–0.62 0.60 0.38–0.80 −0.55
2 232 0.56 0.53–0.60 0.58 0.35–0.78 −0.65
3 274 0.46 0.42–0.49 0.44 0.20–0.71 −1.11
4 277 0.40 0.36–0.43 0.36 0.10–0.62 −1.38
5 229 0.38 0.34–0.42 0.34 0.14–0.60 −1.48
6 132 0.39 0.35–0.44 0.37 0.15–0.58 −1.43
Current positive, mania, and depressive
symptoms¶
o0.001
Not present 504 0.62 0.26 0.60–0.64 0.67 0.45–0.83
Mania only 24 0.58 0.46–0.70 0.63 0.36–0.80 −0.15
Positive symptoms only 577 0.50 0.48–0.53 0.52 0.26–0.74 −0.46
Mania and positive symptoms 48 0.46 0.38–0.53 0.47 0.20–0.69 −0.62
Depressive symptoms only 120 0.41 0.36–0.45 0.42 0.19–0.58 −0.81
Mania and depressive symptoms 14 0.34 0.23–0.44 0.27 0.18–0.49 −1.08
Positive and depressive symptoms 265 0.32 0.29–0.36 0.27 0.11–0.52 −1.16
All symptoms present 61 0.29 0.24–0.34 0.24 0.12–0.44 −1.27
Suicidal ideation: lifetime# o0.001
Not present, ever 536 0.56 0.28 0.54–0.59 0.60 0.32–0.80
At least 1 wk or attempted, ever 685 0.47 0.45–0.49 0.49 0.23–0.70 −0.32
At least 2 wk, ever 105 0.48 0.43–0.54 0.55 0.26–0.71 −0.28
At least 1 mo, ever 287 0.43 0.40–0.47 0.42 0.16–0.66 −0.46
Suicidal ideation: current** o0.001
Not present, past month 1428 0.52 0.28 0.51–0.54 0.55 0.29–0.75
At least 1 wk or attempted, past month 114 0.29 0.25–0.34 0.24 0.09–0.47 −0.83
At least 2 wk, past month 23 0.28 0.20–0.36 0.27 0.08–0.39 −0.86
At least 1 mo, past month 48 0.24 0.17–0.30 0.15 0.08–0.35 −1.01
SD pertains to the reference category.
ANOVA, analysis of variance; AQoL, Assessment of Quality of Life; CI, conﬁdence interval; DIP, diagnostic interview for psychoses; ES, effect
size; ICD-10, International Classiﬁcation of Diseases, Tenth Revision; IQR, interquartile range; SD, standard deviation.
* Modiﬁed Cohen d, with reference category as the ﬁrst category, except for diagnosis for which it is the last category.
† ANOVA, adjusted Wald F ¼ 8.246; df ¼ 4, 1608; P o 0.001.
‡ ANOVA, adjusted Wald F ¼ 43.360; df ¼ 4, 1608; P o 0.001.
§ ANOVA, adjusted Wald F ¼ 4.140; df ¼ 6, 1606; P o 0.001.
|| ANOVA, adjusted Wald F ¼ 24.116; df ¼ 6, 1606; P o 0.001.
¶ ANOVA, adjusted Wald F ¼ 41.887; df ¼ 7, 1605; P o 0.001.
# ANOVA, adjusted Wald F ¼ 13.931; df ¼ 3, 1609; P o 0.001.
** ANOVA, adjusted Wald F ¼ 58.600; df ¼ 3, 1609; P o 0.001.
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V A L U E I N H E A L T H ] ( 2 0 1 8 ) ] ] ] – ] ] ] 7both the SF-6D (mean utility 0.551 and 0.623, respectively) and the
EQ-5D (mean utility 0.537 and 0.665, respectively). Psychosis was
consequently assessed as having no signiﬁcant independent
effect on utility in regression analysis.
The lower assessed utilities for depressive conditions over
psychosis (and other mental disorders) with the EQ-5D, 15D, and
SF-6D are not surprising given that these instruments focus on
physical health and largely or solely capture depressive symp-
toms as a proxy for the entire domain of mental health.
Depressive symptoms are, however, identiﬁed as a major driver
of poorer utility in the current analysis, and, of the major
diagnostic categories, depressive psychosis had the lowest utility.
The cumulative effects indicated for comorbid CVD and
current depressive symptoms are consistent with ﬁndings of
additive effects for comorbid CVD and major depressive disorders
with the AQoL-4D [28]. The assessed effect of CVD on HRQOL is
also consistent with the literature on the effect of CVD on
premature mortality in psychosis [29]. HRQOL (EQ-5D utilities)
has been identiﬁed as an independent predictor of mortality in
patients with type 2 diabetes [30]. Whether AQoL-4D utilities are
a predictor of premature mortality in people with psychotic
illness is worthy of future investigation.
The discriminatory abilities of the AQoL-4D are further
reﬂected in the relatively ﬂat, uniform distribution of utilities
across the decades, the 10 HRQOL bands of the utility scale. In
comparison, the EQ-5D has a highly negatively skewed distribu-
tion, and also has a ceiling effect (the assessment of a utility of
1.00) of about 20% in people with schizophrenia [3,31] compared
with less than 3% in the present study.
The AQoL-4D is thus the ﬁrst generic MAUI that can provide
robust utility assessments in people with psychosis, which
obviates the call for methods other than generic HRQOL instru-
ments (MAUIs) to assess utility in people with psychosis [3].
Ascertaining the primary determinants of, and their relative
contributions to, AQoL-4D utilities in individuals with psychotic
illness will be a focus of future research.
Why the Superior Performance of the AQoL-4D in People with
Psychotic Illness?
The AQoL-4D’s assessment of health as a broader construct,
which gives more weight to social disability than do other
instruments used in this population [7], arguably underpins its
superior performance. This hypothesis is consistent with social
functioning being associated with a large ES in the present study.
In contrast, the EQ-5D and 15D do not consider social relation-
ships at all [8], whereas the SF-6D covers social functioning more
generally, focusing on limitations in social activities (see
Appendix 1 in Supplemental Materials).
The need for a broad construct for HRQOL in people with
mental ill-health was foreshadowed at the outset of develop-
ments in quality-adjusted life-year assessment [32]. Among
individuals with psychotic disorders, “well-being and ill-being,”
“control,” “autonomy and choice,” “self-perception,” “belonging,”
“activity,” “relationships,” and “hope and hopelessness” have been
identiﬁed as the domains of most importance in quality of life
[33]. As such, measuring social disability is imperative in the
assessment of HRQOL in psychotic disorders.
The importance of social disability is also reﬂected in the
nomination of social isolation and loneliness as major challenges
by 37.2% of respondents within the present survey [34]. Of all the
MAUIs discussed, only the AQoL assesses loneliness, which may
be a major factor underpinning its sensitivity in psychotic
disorders.
The importance of social isolation as a determinant of HRQOL
in severe mental illness is also consistent with the results of theAQoL psychosis validation study in which the social relationships
dimension was ranked lower than other scored dimensions [9]. In
contrast, psychological well-being was the lowest scored AQoL
dimension in a study of individuals with major depression [35],
suggesting that the determinants of quality of life may differ
between psychotic and nonpsychotic disorders, and that the
AQoL-4D is sufﬁciently sensitive to capture this. These ﬁndings
highlight the importance of using a measure of HRQOL that
comprehensively captures the varying dimensions affected by
different disorders [36]—one cannot assess what is not captured.
It is acknowledged, however, that the AQoL-4D is the ﬁrst and
the simplest in the suite of AQoL instruments and does not
assess all the domains identiﬁed by Connell et al. [33], for
example, control. The most recent AQoL instrument, the 35-item
AQoL-8D, is speciﬁcally designed to assess mental health prob-
lems [37], and in a comparison of six MAUIs—the AQoL-8D, 15D,
SF-6D, ﬁve-level EQ-5D, Health Utilities Index-3, and Quality of
Well-Being—the AQoL-8D was identiﬁed as the instrument of
choice in conditions in which psychosocial domains are impor-
tant [38]. The present analysis conﬁrms that in the case of severe
mental illness, the 12-item AQoL-4D is also preferred over instru-
ments such as the EQ-5D, SF-6D, and 15D.
Because differences between MAUI utilities are “overwhelm-
ingly attributable to instrument content and scale effects” rather
than nationally derived algorithms [38], the results presented are
believed to be generalizable beyond Australia.Study Limitations
The study was conﬁned to people in contact with public treat-
ment services, and did not include data for those solely in the
care of private providers or those in prisons, nursing homes, or
out of contact with mental health care agencies. Utilities are
likely to differ across such groups.
The AQoL-4D is validated for both self and interviewer
administration, and was read to participants in this study.
Nevertheless, there were more missing utility data for persons
with reading and/or writing difﬁculties. Because reading and/or
writing difﬁculties were associated with large ESs, the assessed
utilities have likely been overestimated. The highest levels of
missing data were for current cognitive functioning and premor-
bid IQ, which may also have led to overestimates.
Finally, published general population norms are likely to be
slight overestimates of HRQOL, because of sampling and weight-
ing procedures, including exclusion of those living in nonprivate
dwellings, which would systematically exclude those with poor
mental health living in supported accommodation or residential
care facilities [13].Conclusions
We have demonstrated that the AQoL-4D is the ﬁrst MAUI to
provide robust HRQOL assessments in psychotic disorders, and
the assessed impacts are profound. The largest variations in
utility were assessed for global independent functioning and
perceived mental health. Of the major diagnostic categories,
depressive psychosis had the lowest utility. The discriminant
ability of the AQoL-4D in the population with psychosis supports
the use of this instrument in the assessment of utility for
economic evaluations, and we provide a suite of utilities that
can be used in future economic modeling studies. As a conse-
quence, interventions for people with psychotic illness can be
assessed on an equivalent basis to interventions for all other
conditions and diseases in resource allocation processes.
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